Description
Mouse Decoy Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Receptor 2 (mDcTRAIL-R2) is highly homologous to mDcTRAIL R1. It is a GPI-anchored mouse TNF receptor super-family member that lacks a cytoplasmic death domain. It is expressed on many cell types, including some tumor cells. It was reported that overexpression of mDcTRAIL-R2 did not induce caspase activation that is characteristic of death receptor signaling. mDcTRAIL-R2 appears to have a negative effect against TRAIL receptors because it lacks an intracellular death domain, and produces a competitive blockage of TRAIL-mediated apoptosis. The role of the DcTRAIL-R2 in apoptosis has not yet been completely clarified.
Product Details
Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 1.0 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.
Excitation Laser
Blue Laser (488 nm) Green Laser (532 nm)/Yellow-Green Laser (561 nm)
GPI-anchored mouse TNF receptor super-family member that lacks a cytoplasmic death domain.
Distribution
Express on many types of cells, including some tumor cells.
Function
Appear to have a negative effect against TRAIL receptors because it lacks an intracellular death domain, and produces a competitive blockage of TRAIL-mediated apoptosis.
Ligand/Receptor
TRAIL
Biology Area
Immunology
Molecular Family
Cytokine/Chemokine Receptors
Antigen References
1. Schneider P, et al. 2003. J. Bio. Chem. 278(7):5444 2. Yagyu S, et al. 2008. Clin Cancer Res. 14 (21):7011 3. Ashkenazi A, et al. 1998. Science. 281:1305
This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.
Follow Us